Despite Recent Gains, Radiopharm Theranostics Insiders Are Still Down AU$29k
Some of the losses seen by insiders who purchased AU$138.4k worth of Radiopharm Theranostics Limited (ASX:RAD) shares over the past year were recovered after the stock increased by 11% over the past week. However, the purchase is proving to be a costly gamble, since losses made by insiders have totalled AU$29k since the time of purchase.
While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.
Radiopharm Theranostics Insider Transactions Over The Last Year
The Independent Non-Executive Director Ian Turner made the biggest insider purchase in the last 12 months. That single transaction was for AU$87k worth of shares at a price of AU$0.029 each. That means that an insider was happy to buy shares at above the current price of AU$0.021. It's very possible they regret the purchase, but it's more likely they are bullish about the company. In our view, the price an insider pays for shares is very important. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.
While Radiopharm Theranostics insiders bought shares during the last year, they didn't sell. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
View our latest analysis for Radiopharm Theranostics
There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).
Have Radiopharm Theranostics Insiders Traded Recently?
Over the last three months, we've seen a bit of insider buying at Radiopharm Theranostics. Independent Non-Executive Director Ian Turner bought AU$14k worth of shares in that time. We like it when there are only buyers, and no sellers. But in this case the amount purchased means the recent transaction may not be very meaningful on its own.
Insider Ownership
Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Our data indicates that Radiopharm Theranostics insiders own about AU$5.4m worth of shares (which is 7.2% of the company). Whilst better than nothing, we're not overly impressed by these holdings.
What Might The Insider Transactions At Radiopharm Theranostics Tell Us?
Our data shows a little insider buying, but no selling, in the last three months. The net investment is not enough to encourage us much. But insiders have shown more of an appetite for the stock, over the last year. The transactions are fine but it'd be more encouraging if Radiopharm Theranostics insiders bought more shares in the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Radiopharm Theranostics. For instance, we've identified 4 warning signs for Radiopharm Theranostics (2 are concerning) you should be aware of.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.